Novo Nordisk Queues Up $830M Suit Over Disappointing Drug
By Caroline Simson · February 18, 2025, 9:02 PM EST
Novo Nordisk is set to initiate an $830 million arbitration claim in New York accusing Singaporean biopharmaceutical company KBP Biosciences of misleading the Danish drugmaker about the potential of a new...
To view the full article, register now.